



Vaccination and Treatments against Viral Hepatitis: Achievements, Challenges and Perspectives

Guest Editors:

Dr. Bárbara Vieira Do Lago

Laboratory of Viral Hepatitis,
Oswaldo Cruz Institute, FIOCRUZ,
Rio de Janeiro 21040-900, Brazil

Dr. Vinicius M. Mello

Viral Hepatitis Laboratory,
Oswaldo Cruz Institute, FIOCRUZ,
Rio de Janeiro, Brazil

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editors

The vaccination era is a major global public health milestone that has led to the eradication of and reduction in infectious diseases. Vaccination has been important in reducing Hepatitis A and B cases in younger age groups in the context of viral hepatitis. In addition, vaccination against HBV, associated with immunoglobulin and prophylactic antiviral use, has led to a 90% reduction in cases of mother-to-child transmission and has also helped preventing Hepatitis D infection. As for the hepatitis C virus, despite the unavailability of a vaccine, the use of antiviral treatments has been promising and several studies for the development of an effective vaccine have been conducted.

Vaccination against hepatitis E is only licensed in China, and more safety studies in children, the elderly, and other special populations are needed for future global deployment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com